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We evaluated by immunohistochemistry the expression of the Bcl-2 and p53 proteins, as markers of apoptosis control, and of
MIB-1, as a marker of cell proliferation, in a series of normal and neoplastic adrenocortical tissues. The specimens were 13
normal adrenals, 13 aldosterone-producing adenomas, 13 non-functioning adenomas and 16 carcinomas. Results were
calculated as percentage of immunostained cells by using speciﬁc antibodies. No p53 protein was detected in any of the
adrenocortical adenomas (functioning and non functioning) or normal adrenals, while p53 was overexpressed in 15 out of 16
carcinomas. In particular, 10 adrenal cancer specimens (62.5%) showed strong staining in a high percentage (range 10–50%)
of the malignant cells. The percentage of Bcl-2 positive cells was higher (P50.05 or less) in non-functioning adenomas
(8.1+1.9%) and in carcinomas (14.9+5.6%) than in normals (2.9+0.9%) and aldosterone-producing adenomas (5.3+1.3%)
since four specimens of the non-functioning adenomas-group (30.7%) and six of the carcinomas-group (37.5%) showed over
10% positivity (cut-off for normal values, set at 90th percentile of our controls). MIB-1 positivity was 0.50+0.36% in normals,
0.54+0.08% in non-functioning adenomas and 0.54+0.08% in aldosterone-producing adenomas. MIB-1 was expressed in all
carcinomas with values (13.7+3.1%) signiﬁcantly (P50.0006) higher than in the other groups. In conclusion, the present data
indicate that the apoptosis control and proliferation activity evaluated by the p53 and MIB-1 proteins are impaired in adrenal
carcinomas but preserved in adenomas, independently of their functional status. Therefore, these immunohistochemical
markers, overexpressed in carcinomas only, may be useful in the diagnosis of malignancy in adrenocortical tumours. Whether
Bcl-2 positivity found in some carcinomas and non-functioning adenomas may constitute, in the latter, a negative prognostic
marker is still unknown.
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The growth and diffusion of cancers, and consequently their
aggressiveness, are dependent on a complicated balance between
several mechanisms, such as neoangiogenesis, release of growth
stimulating and inhibiting factors, apoptosis control and prolifera-
tion activity (Fox, 1997).
While malignant tumours of human adrenocortical glands are
very rare (Wooten and King, 1993), benign adenomas, both non-
functioning and functioning, are common in clinical practice.
However, the apoptosis control and proliferation activity of
neoplasms of the adrenal cortex have not been adequately investi-
gated and results obtained to date are not univocal.
Mutations in the p53 tumour suppressor gene, which constitute
the most common type of genetic alteration in several human
cancers (Velculescu and El-Deiry, 1996), do not seem to be
frequent in adrenocortical tumours (Ohgaki et al, 1993; Reincke
et al, 1994; Reincke et al, 1996). Different results were found in
studies on pathological adrenal cortex (Lin et al, 1994; Reincke et
al, 1994, 1996; Barzon et al, 2001) for what concerns p53 overex-
pression, a well-established immunohistochemical marker of p53
mutations (Davidoff et al, 1991),
Bcl-2, a cellular oncogene which encodes for proteins that inhi-
bit apoptosis, thereby determining resistance to programmed cell
death (Hockenbery et al, 1990, 1993), is overexpressed in different
types of solid tumours (Pilotti et al, 1994; Vargas et al, 1997).
However, Bcl-2 immunoreactivity has been demonstrated not only
in adrenal cortical lesions (cortical hyperplasia, adenomas and
carcinomas) but also in normal cortical tissue (Fogt et al, 1998).
MIB-1, which recognises a nuclear antigen (Ki-67) associated
with all phases of the cell cycle except in resting cells (Gerdes et
al, 1984), is overexpressed in several human tumours and is
commonly considered very useful in the evaluation of tumour cell
growth (Hall and Woods, 1990). Recently it has also been reported
that MIB-1 expression differentiates benign from malignant adre-
nocortical tumours but not adenomas from normal cortex (Iino
et al, 1997; Nakazumi et al, 1998).
The aim of our study was to evaluate, by immunohistochemis-
try, expression of the Bcl-2 and p53 proteins as markers of
apoptosis control and of MIB-1 protein as a marker of cell prolif-
eration, in a series of human normal and neoplastic (adenomas and
carcinomas) adrenocortical tissues.
MATERIALS AND METHODS
Patients and pathology
The study, approved by the local Ethical Committee, involved 55
patients with aldosterone-producing adenomas (n=13, APA), non-
functioning cortical adenomas (n=13, NFA) and adrenocortical
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www.bjcancer.comcarcinomas (n=16, CA). As controls, 13 normal adrenal glands (N)
were studied after removal from patients with renal carcinomas. Clin-
ical and pathological details of our population are shown in Table 1.
Patients with APA showed the typical pattern of the disease with
hypertension (systolic blood pressure 174+7.0 mmHg, mean+s.e.,
diastolic blood pressure 107+3.5 mmHg) hypokaliemia
(2.9+0.2 mmol l
71), low PRA levels (0.18+0.06 ng ml h
71) and
high plasma aldosterone (1298+172 pmol l
71). In patients with
NFA adrenal masses had been incidentally discovered and endocri-
nological investigation had revealed normal catecholamines,
glucocorticoids, androgens and mineralcorticoids in all cases.
Patients with CA had been investigated for abdominal pain in 11
cases and for hyperandrogenism in ﬁve cases. Pathological diagno-
sis of our tumours was based on accepted criteria including
tumour mass, presence of metastasis or recurrence, mitotic ratio,
nuclear grade, necrosis and capsula and/or vascular invasion (Lack,
1997). In particular, tumour necrosis was absent in two, low in
two, moderate in four and wide in eight cases. Staging of CA,
according to the Mac-Farlane criteria (Mac-Farlane, 1958), indi-
cated stage II in six cases, stage III in eight cases and stage IV in
two patients.
After surgery, all NFA and APA were cured while 13 CA died of
local and/or diffuse metastases with a mean(+s.d.) survival of
27.2+31.0 months (range 3–100 months). Three patients were
alive at time of writing of the manuscript (follow-up performed
10 months after surgery).
Specimens
A total of 55 formalin-ﬁxed, parafﬁn-embedded blocks of adrenal
tissues were studied. Five mm sections were stained with haematox-
ilin-eosin for histological evaluation. Five additional mm sections
were used for immunohistochemistry.
Immunohistochemistry
Antibodies The sections were incubated with the following
primary monoclonal antibodies: MAb 124 (DBA, dilution 1:100)
for Bcl-2, MAb DO7 (Novocastra Laboratories, dilution 1:100)
for p53, and MIB-1 (DBA, dilution 1:200) for Ki-67. Incubation
time was 12–24 h at 48C.
Method
Tissue sections stained for MIB-1 were pretreated using 0.1 tryp-
sin with 0.1 calcium chloride buffered to pH 7.6. In order to
unmask the antigens, the slides were microwave treated in
10 mM citrate buffer, pH6, for a total of 10 min. MIB-1 and
p53 sections were incubated with biotin-labelled secondary anti-
body (dilution 1:500) and avidin-biotin complex (Vector
Burlingame, CA, USA) for 30 min respectively. 3-3' diaminoben-
zidine tetrahydrochloride with 0.01 hydrogen peroxide was used
as chromogen. The alkaline phosphatase-anti-alkaline phosphatase
(APAAP) method was used to amplify the Bcl-2 signal. The reac-
tion was developed with alkaline phosphatase containing
naphthol, AS-MX, fast red, and levamisol (APAAP kits DAKO,
Milan, Italy).
Controls
Positive controls consisted of invasive breast carcinoma known to
express MIB-1 and p53 antigens. Positive control for Bcl-2 was
follicular non-Hodgkin lymphoma. Negative controls were
obtained by omitting primary antibodies.
Evaluation of parameters
The positivity index was obtained by counting almost 500 cells of
lesions of normal tissue on three 6250 fields and calculating the
percentage of cells with nuclear (p53 and MIB-1) and cytoplas-
matic (Bcl-2) immunoreactivity. Since in our normal tissues no
immunoreactivity was found for p53 and MIB-1, the specimens
were considered positive when at least 1% of cells showed distinct
nuclear staining. However, in order to reduce possible false positive
results, we also analysed our data by moving the cut-off of normal-
ity to 5%. In contrast, for Bcl-2 the specimens were considered
positive when at least 11% of cells showed intense cytoplasmatic
immunoreactivity, as the cut-off of normal values, calculated as
90th percentile of our controls, proved to be 10%. All parameters
were determined independently by two pathologists (VP and BA)
and discordant cases were solved by simultaneous review of the
specimens. Cases with interobserver differences greater than 5%
were re-evaluated.
Statistics
All data are expressed as mean+s.e.m. Values obtained for each
variable to compare groups were analysed by using the unpaired
t-test and Wilcoxon’s test. Spearman correlation coefﬁcients (r)
were used as parameters of association. Statistical difference was
accepted at P50.05.
RESULTS
Age in the APA and NFA-groups was signiﬁcantly lower than in N
and, among adrenal lesions, tumour size in CA was highest while
that in APA proved to be the lowest (Table 1).
No p53 protein was detected in any sample of N, APA and NFA.
In contrast, p53 was expressed in 15 out of 16 (94%) CA and in 10
specimens the staining involved between 10–50% of the malignant
cells (Figures 1 and 2). Even considering our cut-off of positivity
55%, p53 expression was still elevated, corresponding to 11 out
of 16 cases (68.7%).
APA (5.3+1.3%) and N (2.9+0.9%) -groups showed an aver-
age percentage of Bcl-2 positive cells lower than NFA
(8.1+1.9%) and CA (14.9+5.6%)-groups. No difference was
found between NFA and CA (Figure 3). Analytical data showed
that four specimens of the NFA-group (30.7%) and six of the
CA-group (37.5%) had positivity over 10% (our cut-off of normal
values) (Figure 3 below).
MIB-1 expression was very low (41%) in cortical adenomas
(APA and NFA) and in normal specimens, while strong
immunoreactivity (3–40%) was detected in all CA with mean
values (13.7+3.0%) signiﬁcantly (P50.0001) higher than in
normal adrenals (0.5%), APA (0.53+0.08%) and NFA
(0.53+0.08%) (Figures 4 and 5).
No correlation was found between p53, MIB-1 and Bcl-2 or
between these immunohistochemical markers and clinical or
pathological variables in the APA and NFA-groups. Positive asso-
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Table 1 Clinical and pathological details of normal subjects (N) and of
patients with aldosterone-producing adenoma (APA), non-functioning
adrenocortical adenoma (NFA) and adrenocortical carcinoma (CA).
Mean+s.e.m. and range (in parentheses) are shown
N APA NFA CA
Age (years) 59.8+3.0 47.4+2.6** 49.9+2.9* 53.4+4.4
(38–70) (27–59) (30–72) (19–77)
male/female 9/4 8/5 6/7 9/7
side (R/L) – 4/9 6/7 8/8
tumour size (mm) – 20.0+2.2 41.1+3.28 120.8+13.38{
(5–30) (25–60) (60–250)
*P50.02; **P50.004 vs N. 8P50.0001 vs APA. {P50.0001 vs NFA.
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p53 and tumour necrosis (r=0.530, P50.03) were detected in CA.
DISCUSSION
The aim of our study was to investigate apoptosis control and
proliferation activity in a group of human adrenal neoplasms,
using an immunohistochemical approach. This method presents
some intrinsic limits, both because it does not always reﬂect a
corresponding genetic alteration and because it does not permit
exact quantiﬁcation of the proteins in the tissues. However, immu-
nohistochemistry sometimes appears to be the only procedure able
to detect speciﬁc proteins involved in tumorogenesis and offers the
advantage of detecting the exact intratissutal localisation and the
intracellular distribution of several markers.
It is well-known that the human tumour suppressor p53 is
deemed critical for maintaining genomic stability and homeostasis
(Agarwal et al, 1998). Accordingly, mutations in the p53 gene
constitute the most common type of genetic alteration in human
cancers (Hollstein et al, 1991; Velculescu and El-Deiry, 1996).
However, few data refer to adrenocortical CA and those reported
indicate that p53 mutations are uncommon in these tumours
(Ohgaki et al, 1993; Reincke et al, 1994). Different ﬁndings were
observed by immunohistochemistry. Our study shows frequent
p53 immunoreactivity in CA and other authors (Reincke et al,
1994) reported p53 positivity in about half of their cases. The deﬁ-
nition of positive immunohistochemical staining in this study was
51% because no immunostaining was detected in the specimens
of our controls. However, even when the cut-off of p53 positivity
was moved to 5% in order to reduce possible false positive results,
we obtained similar results with high frequency of immunoreactiv-
ity in CA (68.7%). Since genetic analysis of the specimens could
not be performed, we cannot establish whether the p53 overexpres-
sion we found represents underlying gene mutations or results
from abnormal stabilisation of the wild-type protein leading to
an increase in its half-life. In any case, our ﬁnding indicates that
p53 immunoreactivity is a feature of CA. Different results have
been reported in APA where no or poor p53 immunoreactivity
was found not only in adenomas without p53 mutations (Reincke
et al, 1996) but also in those with ascertained genetic alterations
(Lin et al, 1994; Adleff et al, 1998). The present data conﬁrm these
observations since immunohistochemistry failed to show p53 posi-
tive cells in all 13 APA. All these ﬁndings imply that in APA p53
mutations are likewise uncommon but do not exclude the possibi-
lity that in these adenomas the immunohistochemical method may
have low sensitivity. Indeed a mutant p53 protein may be not
recognisable by the antibody, deletion mutations do not necessarily
induce abnormal p53 protein and in the case of missense muta-
tions several events may be required for p53 overexpression
(Casey et al, 1996). More homogeneous data on the p53 protein
have been observed in NFA. No genetic p53 mutation and no
p53 immunoreactivity was detected in isolated cases (Reincke et
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Figure 1 Mean percentage (+s.e.m.) of p53 positive cells in normal cor-
tex (N), Aldosterone-producing adenomas (APA), non-functioning adeno-
mas (NFA) and carcinomas (CA).
Figure 2 Adrenocortical carcinoma with several p53 immunoreactive
cells.
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Figure 3 Mean percentage (+s.e.m.) of Bcl-2 positive cells in normal
cortex (N), Aldosterone-producing adenomas (APA), non-functioning ade-
nomas (NFA) and carcinomas (CA). The statistical difference is shown
(above). Bcl-2 individual data in APA, NFA and CA: the dotted line repre-
sents the upper limit of normal calculated as 90th percentile of our controls
(below).
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with these data since none of the NFA patients studied was positive
for p53 immunoreactivity.
Taken together, the present results indicate that p53 is a useful
immunohistochemical marker to distinguish benign from malig-
nant adrenal tumours since it proved to be overexpressed in
several carcinomas and never expressed in functioning and non-
functioning adenomas.
Bcl-2 is a cellular oncogene which encodes for proteins that
inhibit apoptosis, thus determining resistance to programmed cell
death (Hockenbery et al, 1990, 1993). Bcl-2 expression has been
reported in normal tissues but also in different types of solid
tumours (Pilotti et al, 1994; Vargas et al, 1997). However few
studies have investigated this protein in adrenal glands. The most
extensive study (Fogt et al, 1998) indicated that Bcl-2 is overex-
pressed in normal adrenal cortex, without distinct staining
difference between normal and pathological tissue (hyperplasia,
adenomas and carcinomas). Our results conﬁrm that Bcl-2 positiv-
ity is detectable in normal adrenals. In contrast, cortical adenomas
and carcinomas showed heterogeneous Bcl-2 expression. Some CA
(37.5%) and NFA (30.7%) had strong positivity, while in the
remaining and in all APA the number of Bcl-2 positive cells was
similar to normal tissue. The prognostic signiﬁcance of this parti-
cular immunohistochemical pattern observed in some NFA is
unknown.
Evaluating our data, we observed a strong discrepancy in the
expression rate of Bcl-2 and p53 in CA. We have no clear explana-
tion for this ﬁnding, although it may depend on the fact that the
two markers involve different and independent mechanisms of
apoptosis control. Thus, in human tumours the expression of
Bcl-2 and mutant p53 does not always coexist, even if both
markers block programmed cell death. Accordingly, a lack of rela-
tion and even an inverse association between Bcl-2 and p53 were
found in breast carcinomas (Leek et al, 1994; Siziopiku et al,
1996; Viacava et al, 1999) and in parathyroid adenomas (Naccarato
et al, 1998).
A useful tool to examine cell proliferation activity consists in
immunohistochemical analysis by MIB-1, an antibody that recog-
nises Ki-67, a cell cycle-related nuclear antigen (Gerdes et al,
1984; Hall and Woods, 1990). A recent study reported no differ-
ence in MIB-1 expression between normal cortex and functioning
(Iino et al, 1997; Nakazumi et al, 1998) and non-functioning corti-
cal adenomas (Gerdes et al, 1984). In contrast, MIB-1 may
differentiate adenomas from carcinomas of the adrenal cortex
and may predict the biological behaviour of adrenocortical CA
(Suzuki et al, 1992; Goldblum et al, 1993; Sasano et al, 1995; Iino
et al, 1997; Nakazumi et al, 1998). Our results conﬁrm these data,
showing that in cortical adenomas, independently of their function,
MIB-1 expression is similar to that in normal cortex, while in
malignant tumours MIB-1 positivity appears to be strongly and
constantly present.
In conclusion, the present data indicate that the apoptosis
control and proliferation activity evaluated by the p53 and MIB-
1 proteins are impaired in CA but preserved in adenomas, inde-
pendently of their functional status. Therefore, these
immunohistochemical markers, overexpressed in CA only, may
be useful in the diagnosis of malignancy in adrenocortical tumours.
Finally, our results show that Bcl-2 overexpression may occur in
CA but also in some NFA. Whether Bcl-2 positivity constitutes a
negative prognostic marker in NFA is, at present, unknown.
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